No quarterly revenue total was found in PERSPECTIVE THERAPEUTICS, INC.'s SEC filings.
Perspective Therapeutics, Inc. (CATX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$34.8 million. As of Jun 30, 2026 it held $236.9 million in cash and investments and $4.0 million in total debt.
Revenue
—
Net income
$-26.79M
-24.7% vs year-ago quarter
Operating cash flow
$-20.65M
-3.5% vs year-ago quarter
Free cash flow
$-34.84M
-66.1% vs year-ago quarter
EPS
$-0.22
+24.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
114.15M
+53.7% vs year-ago quarter
Net cash
$232.91M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CATX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 728387
- Former names
- IsoRay, Inc. (until Feb 16, 2023); Isoray, Inc. (until Feb 16, 2023); CENTURY PARK PICTURES CORP (until Aug 3, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$29.3M | -$28.3M | -$39.8M | -$27.9M | -$24.0M |
| Net income | -$26.8M | -$26.2M | -$37.5M | -$26.0M | -$21.5M |
| Diluted EPS | -$0.22 | -$0.25 | -$0.50 | -$0.35 | -$0.29 |
| Operating cash flow | -$20.6M | -$31.5M | -$24.7M | -$16.3M | -$20.0M |
| Free cash flow | -$34.8M | -$38.3M | -$29.7M | -$18.3M | -$21.0M |
| Total assets | $392.0M | $410.8M | $267.0M | $294.8M | $310.7M |
| Total liabilities | $68.2M | $63.3M | $59.9M | $52.6M | $45.0M |
| Stockholders' equity | $323.9M | $347.4M | $207.0M | $242.2M | $265.7M |
| Cash and investments | $236.9M | $270.9M | $144.7M | $174.1M | $191.6M |
| Total debt | $4.0M | $4.2M | $3.3M | $3.3M | $3.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 6, 2026 | Nov 6, 2026 |
| 8-K |
Current report
Other events
|
Nov 6, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
All 1004 Perspective Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.